Supreme Court denial of Glivec patent clarifies limited intellectual property protection and discourages future innovation in India
- Details
- Category: Novartis
A decision issued by the Indian Supreme Court regarding the Novartis breakthrough medicine Glivec® (imatinib mesylate) provides clarification on Indian patent law and discourages innovative drug discovery essential to advancing medical science for patients.
FDA perspective published in the New England Journal of Medicine reinforces safety of Pradaxa® (dabigatran etexilate)
- Details
- Category: Boehringer Ingelheim
A new perspective from the U.S. Food and Drug Administration (FDA) published in the New England Journal of Medicine(1) states that the agency has not changed its recommendations regarding Pradaxa® (dabigatran etexilate), following the November 2012 Mini-Sentinel evaluations.(2)
Lundbeck and Otsuka further expand their alliance and enter into collaboration
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced a license and development agreement for Lu AE58054, a selective 5HT6 receptor antagonist currently in development for the treatment of Alzheimer's disease.
AstraZeneca settles litigation over CRESTOR patent
- Details
- Category: AstraZeneca
AstraZeneca today announced that it has entered into a settlement agreement in its US patent infringement litigation against Watson Laboratories, Inc., Actavis, Inc. (formerly known as Watson Pharmaceuticals, Inc.), and EGIS Pharmaceuticals regarding Watson's proposed rosuvastatin zinc product.
Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies
- Details
- Category: Novartis
New data presented at the 65th annual meeting of the American Academy of Neurology (AAN) show Gilenya® (fingolimod), the first oral disease modifying therapy approved to treat relapsing forms of multiple sclerosis (MS), significantly and consistently reduced the rate of brain volume loss.
Amgen announces top-line results of phase 3 talimogene laherparepvec trial in melanoma
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) announced top-line results from the Phase 3 trial in melanoma, which evaluated the efficacy and safety of talimogene laherparepvec for the treatment of unresected stage IIIB, IIIC or IV melanoma compared to treatment with subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF).
$500,000 endowment gift from the GlaxoSmithKline Foundation
- Details
- Category: GlaxoSmithKline
The Children's Hospital of Philadelphia is proud to announce a $500,000 gift from the GlaxoSmithKline (GSK) Foundation. The donation will greatly enhance the GlaxoSmithKline Hope for Families Fund, an endowment fund which was established in 2008 with a $1 million gift from The GlaxoSmithKline Foundation and GlaxoSmithKline, and matched by The Children's Hospital of Philadelphia.
More Pharma News ...
- AstraZeneca to establish strategic R&D centres
- Merck announces collaboration with nordic Bioscience for Sprifermin
- Shire acquires Premacure AB
- American College of Cardiology and Boehringer Ingelheim collaborate to advance physician education
- Bayer to collaborate with the Children's Hospital & Research Center Oakland to fight rare blood diseases
- United States Patent & Trademark Office grants Pfizer reissue patent for Celebrex®
- Australia Federal Court holds CRESTOR patents invalid